Wegovy (semaglutide 2.4 mg) is the higher-dose formulation of semaglutide developed specifically for weight management. Unlike Ozempic — which is registered for type 2 diabetes and used off-label for weight loss — Wegovy is SAHPRA-registered in South Africa as a registered treatment for obesity. This guide explains everything South African patients need to know: what it is, how it works, the clinical trial evidence, what to expect, and how to access it.
Quick summary: Wegovy is the same active ingredient as Ozempic (semaglutide), just at a higher dose (2.4 mg) and licensed specifically for weight loss. STEP-1 trial data showed an average 14.9% body weight loss over 68 weeks — making Wegovy one of the most effective non-surgical weight loss medications available.
Wegovy is a once-weekly subcutaneous injection containing semaglutide 2.4 mg — a GLP-1 receptor agonist. It mimics the action of a natural hormone (glucagon-like peptide-1) that regulates appetite, slows gastric emptying, and improves blood sugar control.
The result: significantly reduced hunger, increased satiety after meals, and meaningful sustained weight loss when combined with lifestyle changes.
Wegovy's approval is based on the STEP (Semaglutide Treatment Effect in People with obesity) clinical trial programme — one of the largest weight management trial programmes ever conducted. Published in the New England Journal of Medicine, STEP-1 enrolled 1,961 adults with obesity over 68 weeks.
Subsequent STEP trials (STEP-3, STEP-4, STEP-5, STEP-8) confirmed the durability of weight loss, demonstrated benefits across diverse populations, and showed that continued treatment maintains results — while discontinuation is associated with weight regain over time.
Both medications contain semaglutide as the active ingredient — but they are not interchangeable products:
| Feature | Wegovy | Ozempic |
|---|---|---|
| Active ingredient | Semaglutide | Semaglutide |
| Maximum dose | 2.4 mg/week | 2.0 mg/week |
| SAHPRA indication | Obesity / weight management | Type 2 diabetes |
| Weight loss use | On-label (registered) | Off-label |
| Average weight loss | ~15% (STEP-1) | ~12% (off-label data) |
| Pen colour | Pale blue (varies by dose) | Pale blue |
The practical difference: Wegovy reaches a higher dose specifically optimised for weight loss, and has the registered indication on its product label — meaning prescribing for weight management is on-label rather than off-label.
Wegovy uses a gradual dose-escalation schedule to minimise side effects:
| Week | Dose | Purpose |
|---|---|---|
| Weeks 1–4 | 0.25 mg/week | Starter — body adjusts to medication |
| Weeks 5–8 | 0.5 mg/week | First step-up |
| Weeks 9–12 | 1.0 mg/week | Second step-up |
| Weeks 13–16 | 1.7 mg/week | Third step-up |
| Week 17 onwards | 2.4 mg/week (maintenance) | Full therapeutic dose |
It takes approximately 16–17 weeks to reach the full maintenance dose. This slow escalation is intentional — it dramatically reduces side effects compared to rapid dose escalation.
The side effect profile of Wegovy mirrors that of other GLP-1 medications. From STEP-1 trial data, the most common side effects are gastrointestinal:
Side effects are most pronounced in the first 4–8 weeks and after each dose increase. The vast majority resolve or significantly improve over time. For full management strategies, see our guide on GLP-1 side effects.
Wegovy is indicated for adults who meet one of the following criteria:
It is most appropriate as part of a comprehensive treatment programme that includes nutrition, physical activity, and behavioural support.
Contraindications: Wegovy should not be used in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2), a history of pancreatitis, severe gastrointestinal disease, or during pregnancy and breastfeeding. Your doctor will assess your full medical history during consultation.
Wegovy pricing in South Africa typically falls between R2,800 and R4,200 per month at the maintenance dose, depending on the dispensing pharmacy. Pricing for lower starter doses is usually slightly lower. For a complete cost breakdown of all GLP-1 medications, see our 2026 cost guide.
Because Wegovy is SAHPRA-registered for weight management, any HPCSA-registered doctor can prescribe it for eligible patients. The process is straightforward:
Book a 15-minute online consultation with a HPCSA-registered South African doctor. R700 first visit (consult + script). Renewals R350.
Book Consultation →